Preliminary results for the first quarter of 2011

During the process leading up to the public offer by Medivir AB (publ)
("Medivir") to the shareholders and the holders of listed warrants in BioPhausia
AB (publ) ("BioPhausia"), Medivir has been given access to certain preliminary
information regarding BioPhausia's financials for the first quarter of 2011.

In order to provide all owners in BioPhausia and the stock market with the
corresponding information, the Board of Directors of BioPhausia announces the
following:

BioPhausia's net sales for the period January-March, 2011, amounted preliminary
to approximately SEK 134m, compared to SEK 112m for the corresponding period in
2010.

Earnings before depreciation and amortisation (EBITDA) for January-March, 2011,
amounted preliminary to approximately SEK 31m (including non-recurring income of
approximately SEK 2m), compared to SEK 10m for the corresponding period in 2010.

The information regarding the first quarter of 2010 is adjusted for net sales
and EBITDA relating to the OTC portfolio of pharmaceuticals that was divested in
2010.

BioPhausia's full interim report for the first quarter of 2011 will be published
on May 10, 2011.


                           Stockholm, April 11, 2011

                              BioPhausia AB (publ)

                             The Board of Directors

BioPhausia AB (publ) discloses the information provided herein pursuant to the
Securities Market Act and the Takeover Rules. The information was submitted for
publication on April 11, 2011 at 08:30 AM.

For further information, please contact:
Maris Hartmanis, CEO BioPhausia AB (publ), tel +46-8-407 64 30


[HUG#1505025]